160 related articles for article (PubMed ID: 31219316)
1. The effect of Oncotype DX
Rabie MA; Rankin A; Burger A; Youssef M
Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
[TBL] [Abstract][Full Text] [Related]
2. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
3. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
4. Benefits of introduction of Oncotype DX
Green N; Al-Allak A; Fowler C
Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
[TBL] [Abstract][Full Text] [Related]
5. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
[TBL] [Abstract][Full Text] [Related]
6. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
8. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
9. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
10. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
11. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
[TBL] [Abstract][Full Text] [Related]
13. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
14. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA; Hanna H; Nassar A
Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
[TBL] [Abstract][Full Text] [Related]
15. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Rizki H; Hillyar C; Abbassi O; Miles-Dua S
Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
17. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
18. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
19. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
[TBL] [Abstract][Full Text] [Related]
20. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]